


Urinary Tract Infection (UTI) –Treatment Algorithm



Note: All antibiotics listed (except Fosfomycin and Ceftriaxone) must be adjusted for renal insufficiency. Avoid Nitrofurantoin in CrCL 40-50 mL/min (drug will not reach bladder to adequately treat cystitis). Nitrofurantoin and Fosfomycin do not penetrate renal parenchyma and should not be used to treat pyelonephritis.

****For management of candiduria, please refer to Table 4**

The above guidelines are recommendations based on the available literature and are not intended to replace clinical judgment.

Please note these recommendations reflect local antimicrobial susceptibility patterns and may differ from published guidelines.

Table 1. Asymptomatic Bacteriuria/ Acute Cystitis and Pyelonephritis in Pregnancy⁷**For asymptomatic bacteriuria/acute cystitis:***First line:*

- Nitrofurantoin 100 mg PO BID x 5-7 days (avoid near-term⁸)
- Cephalexin 500 mg PO QID x 5-7 days⁵

Second line:

- Cefuroxime 250-500 mg PO BID x 5-7 days
- TMP/SMX 1 DS tab PO BID x 5-7 days (avoid in 1st trimester and near term; supplement with multivitamin containing folic acid)

For Group B Strep:

- Penicillin VK 500 mg PO QID x 5-7 days
- Amoxicillin 500 mg PO TID x 5-7 days

For pyelonephritis: *IV therapy required until afebrile x 48 hrs, then switch to PO antibiotics if appropriate*

- Ceftriaxone 2g IV q 24hrs
- Gentamicin (dosing per pharmacy)
- Duration of treatment: 10-14 days total

Table 2. Pyelonephritis**Empiric Outpatient:** *Consider initial dose of a parenteral agent*

- Ceftriaxone 1-2 g IV/IM x 1
- Gentamicin 5 mg/kg IV/IM x 1
- Ciprofloxacin 400 mg IV x 1 (not necessary if functioning GI tract)

Followed by

- Ciprofloxacin 500 mg PO BID
- Levofloxacin 750 mg PO daily
- Cefuroxime 500 mg PO BID

Empiric Inpatient⁶:

- Ceftriaxone 1-2 g IV once daily
- Gentamicin (dosing per pharmacy)
- Tobramycin (dosing per pharmacy)
- Piperacillin/tazobactam 3.375 g IV Q 8hrs
- If suspected Enterococcus spp. infection: Ampicillin 2 g IV Q 4hrs

Duration of Treatment:

- If treated with Ciprofloxacin: 7 days total
- If treated with Levofloxacin: 5 days total
- If treated with beta-lactam: 10-14 days total

Table 3. Catheter-Associated UTI

- Treatment of asymptomatic bacteriuria is NOT recommended
- Indwelling urinary catheters should be removed as soon as they are no longer required
- If an indwelling catheter has been in place for >2 weeks at the onset of CA-UTI and is still indicated, replacing the catheter is recommended
- If treatment required, please refer to recommendations for complicated UTI

Table 4. Candiduria

- For asymptomatic patients, candiduria often represents colonization. Removal of risk factors, i.e. indwelling catheters, is often sufficient to eradicate candiduria
- Consider ID-consult for non-*C. albicans* candiduria

The above guidelines are recommendations based on the available literature and are not intended to replace clinical judgment.
Please note these recommendations reflect local antimicrobial susceptibility patterns and may differ from published guidelines.

1. General management:
 - Only perform urine cultures if patient is symptomatic OR in patients who cannot provide history (i.e. intubated, dementia) and have sepsis without another source
 - Once culture and sensitivities are available, switch to narrow spectrum if possible
 - Follow-up cultures are NOT necessary if patient shows clinical improvement
2. Positive UA/UC: Leukocyte esterase (+), nitrite (+), >10 WBC/hpf, or culture $\geq 10^5$ organisms /mL ($\geq 10^3$ organisms /mL in catheter urine specimen)
3. If culture MRSA positive, consider presentations of staphylococcal bacteremia (ID consult recommended)
4. Presentation variable dependent on host factors (i.e. elderly may only present with mental status changes, catheterized patients may only have fever, & quad/paraplegics may have fever and increased spasticity or autonomic dysreflexia)
5. Cephalexin susceptibility testing unreliable for MIC>4, please refer to cefuroxime susceptibilities or switch to another agent
6. Initial intravenous (IV) therapy is preferred until patient remains afebrile x 48 hrs, then switch to PO therapy
7. Cultures showing mixed gram-positive bacteria, lactobacilli, and Staphylococcus species (other than *S. saprophyticus*) may be presumed to be contaminants and may not be treated
8. Avoid nitrofurantoin if 38-42 weeks gestation in G6PD-deficient mothers due to risk of maternal & fetal hemolytic anemia

Frequently Asked Questions:

Q: Is it necessary to repeat urine cultures after treatment with antibiotics?

A: Follow up cultures are NOT necessary if the patient is clinically improving and/or is asymptomatic as it may lead to unnecessary antibiotic use.

Q: Is antibiotic prophylaxis recommended for recurrent UTIs?

A: Antibiotic prophylaxis may be considered in women with ≥ 2 urinary tract infections in 6 months or ≥ 3 urinary tract infections in 12 months. The decision must take into consideration frequency and severity of UTI versus adverse effects, such as adverse drug reactions, *C. difficile* colitis, and antibiotic resistance. Several types of management strategies exist (i.e. continuous antimicrobial prophylaxis, post-coital prophylaxis, and patient self-treatment). The type of strategy depends on patient-specific factors, as well as physician/patient preference.

References:

1. Nicolle, L.E., et al. IDSA Guidelines for the Diagnosis and Treatment of Asymptomatic Bacteriuria in Adults. *Clinical Infectious Diseases*. 2005; 40:643–54
2. Hooton, T.M., et al. Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. *Clinical Infectious Diseases*. 2010; 50:625–663
3. Gupta, K., et al. International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clinical Infectious Diseases*. 2011;52(5):e103–e120
4. Pappas, P.G., et al. Clinical Practice Guidelines for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. *Clinical Infectious Diseases*. First published online December 16, 2015 doi:10.1093/cid/civ933
5. American College of Obstetricians and Gynecologists Committee on Obstetric Practice: ACOG Committee Opinion No. 494: Sulfonamides, nitrofurantoin, and risk of birth defects. *Obstet Gynecol*. 2011; 117:1484-5.
6. Hynes, N., and Melia, M. Urinary Tract Infections in Pregnancy. *John Hopkins Antibiotic Guide*. 2013.
7. DeMaio, James. Urinary Tract Infection, Complicated (UTI). *John Hopkins Antibiotic Guide*. 2013.
8. Saskatoon, A.E., et al. Recurrent Urinary Tract Infection. *J Obstet Gynaecol Can*. 2010; 32(11): 1082-1090.
9. Lexicomp Online®. Hudson, Ohio: Lexi-Comp, Inc.; March 1, 2015.

The above guidelines are recommendations based on the available literature and are not intended to replace clinical judgment.